Allogeneic hematopoietic stem cell transplantation for lymphoma
- PMID: 15072616
- DOI: 10.3816/clm.2004.n.004
Allogeneic hematopoietic stem cell transplantation for lymphoma
Abstract
For patients with relapsed or refractory Hodgkin's or non-Hodgkin's lymphomas, allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option when autologous HSCT fails to achieve durable remission or is deemed inappropriate. Allogeneic HSCT can result in long-term survival even in patients with refractory lymphomas. The efficacy of allogeneic HSCT is attributed, at least in part, to an immune-mediated graft-versus-lymphoma (GVL) effect that can also be associated with significant toxicity resulting from graft-versus-host disease. However, clinical evidence of a potent GVL effect is inconsistent. Reduced-intensity conditioning before allogeneic HSCT can facilitate the use of this treatment in older patients and those at high risk. The decrease in toxicity with reduced-intensity regimens may be associated with a loss of antitumor effects. Patients with lymphoma should be selected for allogeneic HSCT on the basis of characteristics that strongly influence transplant outcomes, including histology, chemosensitivity, and donor source.
Similar articles
-
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.Hematol Oncol. 2017 Mar;35(1):17-24. doi: 10.1002/hon.2201. Epub 2015 Mar 18. Hematol Oncol. 2017. PMID: 25782369
-
Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.Leuk Lymphoma. 2003;44 Suppl 3:S99-105. doi: 10.1080/10428190310001623694. Leuk Lymphoma. 2003. PMID: 15202532 Review.
-
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.Bone Marrow Transplant. 2004 May;33(10):1011-4. doi: 10.1038/sj.bmt.1704489. Bone Marrow Transplant. 2004. PMID: 15064693 Clinical Trial.
-
[Allogeneic transplantation in malignant lymphoma].Dtsch Med Wochenschr. 2001 Sep 28;126(39):1062-9. doi: 10.1055/s-2001-17492. Dtsch Med Wochenschr. 2001. PMID: 11602913 German.
-
The allogeneic effect in non-Hodgkin's lymphoma.Leuk Lymphoma. 2003;44 Suppl 3:S91-7. doi: 10.1080/10428190310001623702. Leuk Lymphoma. 2003. PMID: 15202531 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical